Armat Group
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Armira
Armira is an investment holding company focused on providing entrepreneurial capital for long-term partnerships. They aim to be the preferred investment partner for family investors and entrepreneurs seeking to invest in medium-sized businesses and resilient growth companies. For entrepreneurs looking for co-owners, they aim to be a trusted partner for the next growth phase. The firm manages approximately 5 billion EUR and invests in leading family businesses and growth companies in the DACH region and adjacent markets. Their investment approach is supported by an investor base consisting of families, entrepreneurs, and long-term entrepreneurial capital. Armira operates through three main investment strategies: Armira Mittelstand, Armira Growth, and Armira Opportunities. Armira Mittelstand invests in majority stakes in growing "Hidden Champions" in DACH, Northern Italy, and beyond. Armira Growth provides growth capital to European tech companies. Armira Opportunities focuses on significant minority investments in well-established family businesses within health, life sciences, or tech sectors.
Armira Growth
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Arrowfield Capital
Arrowfield Stud, established in 1985, stands as one of the world's foremost thoroughbred stud farms. Founded by John Messara AM, it gained prominence as the launch-pad for breed-shaper Danehill and the home of Champion Sires Redoute’s Choice, Flying Spur, Not A Single Doubt & Snitzel. The stud has been the source of 88 Group 1 winners and the vendor of 85 million-dollar yearlings since 2001. Arrowfield employs 120 people across its stallion, broodmare, yearling, and racing operations. Located on 2500 acres in the fertile Segenhoe Valley near Scone, in the Upper Hunter region of New South Wales, Australia, Arrowfield is dedicated to breeding and raising elite equine athletes. The stud's commitment extends to realizing the racing dreams of its clients through a combination of first-class personnel and exceptional thoroughbreds. Arrowfield continues to shape the landscape of thoroughbred breeding and racing on a global scale.
Art-Invest Real Estate
Art-Invest Real Estate positions itself as a project developer, asset manager, and long-term investor focused on creating sustainable value in the real estate market. Their approach centers around innovation, creativity, and a commitment to projects that positively impact society and the environment. They emphasize creating added value for all stakeholders, not just for themselves, and aim to shape the future through responsible and sustainable development.
Artisanal
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Arweave
Arweave's investment thesis centers around permanent and decentralized data storage. They envision a future where critical information is preserved indefinitely and web applications operate in a truly decentralized and neutral environment. The Arweave network operates as a permanent, decentralized web built within an open ledger, similar to Bitcoin but for data, and has wide adoption, with a stable and mature protocol. The company focuses on supporting applications that leverage this permanent storage for various uses, including preservation of important data and development of decentralized applications. Arweave's strategy appears to be ecosystem-centric, as the website describes itself as a map guiding users to learn about, use, and build on Arweave. It focuses on developing a community around this permaweb. Investment is likely directed towards developers and companies contributing to the Arweave ecosystem. Arweave's strategy is oriented towards promoting growth and adoption of permaweb technology by expanding the number of applications and use-cases, demonstrating its reliability, and developing a community.
Ascend
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Ascend Capital Partners
Ascend Capital Partners is a global venture capital firm that invests its own capital and partners with disruptors to build global ventures. They are global builders with experience across Eastern and Western markets, leveraging deep cross-cultural insight and global networks to invest in and support founders with the strategies and partnerships needed to scale. The firm focuses on backing early-stage disruptors in medtech and mobility with the potential to scale across Europe, Asia, and the U.S., building ecosystems through investments in complementary technologies to drive enduring impact. They emphasize a founder-first approach, committed to long-term value creation, and working closely with founders as trusted partners throughout their journey.
Ascenion
Ascenion GmbH is a knowledge and technology transfer company focused on academic life science research. They operate as a bridge between research institutions and industry, aiming to protect, develop, and commercialize innovative ideas. Ascenion initiates and finances start-ups, provides services to inventors and founders, and helps industry and investors discover opportunities for innovation. They manage a portfolio of over 700 technologies and research materials, facilitating the transfer of these assets to companies that can further develop and commercialize them. Their activities span from initial IP protection and development to financing and strategic support for start-ups, and ultimately to licensing and partnerships with established industry players. Ascenion's core strategy revolves around identifying promising research outputs from its partner institutes, securing intellectual property, and then de-risking and developing these technologies to a point where they are attractive for commercialization. This often involves initiating and supporting start-up companies, providing them with seed funding, management expertise, and access to Ascenion's network of industry contacts. The firm also works closely with established companies to license and co-develop technologies, creating value for both the research institutions and the industry partners. Ascenion's partnership with the LifeScience Foundation underlines its commitment to translating academic discoveries into real-world applications. The company plays a critical role in the life science ecosystem by accelerating the development and commercialization of innovative technologies, ultimately contributing to advancements in healthcare and other related fields. They also actively engage in knowledge sharing and collaboration through workshops and events, fostering a vibrant community of technology transfer professionals and entrepreneurs.
Ascension
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Ascenta Capital
Ascenta Capital focuses on translating scientific innovation into meaningful medicines for patients. They make concentrated investments in biotech companies, particularly those in Phase 1 and 2 clinical development, and those with multi-medicine platform technologies. Ascenta aims to support management teams with strategic and operational experience, contributing beyond capital with strategic guidance, connections, and resources to help partners scale effectively and sustainably. They emphasize a patient-centered approach, investing in innovations that have the potential to make a meaningful difference in patients' lives, keeping patient needs at the heart of every decision. Ascenta Capital targets companies that have development candidates, translating their preclinical science into early human safety and efficiency data. The firm sees opportunity in multi-medicine platforms, recognizing the complex questions of growth, strategy, and value creation that these platforms present, offering asymmetric upside potential. The firm believes that the biotech renaissance is in full swing, driven by a global convergence of biological and chemical insights, life science technology, data analytics, talent, and capital. The firm operates under a set of core values, including originating conviction, acting decisively, being collaborative, and staying nimble. They are driven by the understanding that patients are waiting and that the essence of biopharma is delivering innovative medicines to address major unmet needs. They emphasize close collaboration with management teams, scientists, clinical investigators, and other investors to achieve this shared goal.
Asgard
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
AshGrove Capital
AshGrove Capital is a pan-European specialty lender providing tailored credit solutions to small and medium-sized B2B software and services companies. They focus on delivering credit solutions to companies with a minimum of €5 million ARR. With initial investments typically ranging from €10 million to €50 million, AshGrove provides funding to support mid-market companies looking to execute on a wide range of transaction types. They differentiate themselves by being a thematic investor with a deep understanding of business models within their dedicated sectors, enabling them to create bespoke funding solutions for founder-led and sponsor-backed companies. AshGrove's investment approach revolves around providing senior secured, non-dilutive capital to support the growth and strategic ambitions of their portfolio companies. They offer flexible financing options that cater to a wide array of objectives, including ARR financing, acquisition financing, organic growth investment, debt refinancing, dividend recapitalization, and "war-chest" facilities. Their underwriting process is value-driven, allowing them to be flexible and provide recurring revenue-based financing to businesses investing in growth. Beyond capital, AshGrove operates as a partner to management teams, offering advice and strategic insights. They help portfolio companies enhance go-to-market strategies, optimize finance operations, connect them to a larger ecosystem of potential customers, partners, M&A targets, and buyers, and engage in regular dialogues to optimize organic and inorganic growth initiatives. AshGrove aims to identify and prioritize the highest-return-on-investment action items, enabling companies to focus on what drives the most value. They are particularly keen to support acceleration of growth via investment through zero/negative EBITDA profitability, execution of license-maintenance to SaaS transition, and retention of full.
Asia Investment Capital
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Asia Pacific Investment Partners
Asia Pacific Investment Partners (APIP) focuses on investments in emerging markets across Asia. The firm's strategy revolves around identifying and capitalizing on opportunities in developing economies with high growth potential. APIP's investment approach extends to various sectors including real estate, construction, food and beverage retail, and metals. The company focuses on long-term investments and aims to foster sustainable growth within its portfolio companies, positioning itself as a strategic partner in the development of emerging economies. Their research division provides deep insights into the economies of countries like Mongolia, Myanmar, China, and others, allowing for informed investment decisions. APIP's strategy includes a mix of direct investments and operational involvement in its portfolio companies, showcasing a hands-on approach to value creation and growth.
Asian Development Bank Ventures (ADBV)
The Asian Development Bank (ADB) is evolving from a financier to a comprehensive partner, aiming to create conditions for the private sector to invest with confidence and deliver lasting impact in Asia and the Pacific. ADB seeks to address the challenge of aligning risk pricing, policy signals, and the conversion of strong ideas into investable projects. They are focused on mobilizing capital, technology, and expertise into emerging markets in Asia and the Pacific at a sufficient scale. ADB's new Advisory Group is guiding this transformation. ADB aims to accelerate resilient infrastructure and economic development in developing countries across Asia and the Pacific. They are partnering with organizations like the Qatar Fund for Development to cofinance and jointly initiate projects across the region, particularly in transport, urban development, and energy. This collaboration aims to unlock development finance for communities and support innovative sectors that are often underfunded. ADB's approach includes strengthening climate adaptation and water resource management, as well as disaster risk reduction, particularly in high-mountain regions. They mobilize global capital to support climate-resilient infrastructure and livelihoods, integrated water resource management, early warning systems, and disaster risk reduction through initiatives such as green bonds, focusing specifically on glacier melt awareness and related projects. This aims to address the threats to water security and livelihoods of the billions of people who rely on mountain rivers for drinking water, agriculture, and energy. ADB is committed to quality, sustainability, and value for money in its projects, as demonstrated by the implementation of merit point criteria (MPC) for evaluating internationally advertised contracts. The organization also focuses on protecting and restoring wetlands, emphasizing nature-based solutions with partner organizations and communities, especially regarding migratory bird routes like the East Asian–Australasian Flyway. They are one of the world's most significant routes, but it’s also one of the most at risk.
Asif Ventures
ASIF Ventures is an Amsterdam-based VC fund supporting student and recent graduate founders from the University of Amsterdam (UvA) and Vrije Universiteit (VU) from the very beginning. Founded in 2017 by students, ASIF was created to back young founders when traditional investors wouldn't. They aim to give students and recent graduates in Amsterdam a real shot at entrepreneurship, backing bold ideas at their earliest stage with capital, community, guidance, and belief. ASIF does more than just invest; they connect founders with the resources, network, and guidance they need to turn ideas into real companies, serving as a launchpad for future entrepreneurs. ASIF targets early-stage funding opportunities for student and recent graduate-led startups in Amsterdam. They provide not only financial capital but also act as a community, offering guidance and support to these young founders. Their focus is on backing bold ideas at their earliest stage, where traditional investors may be hesitant. Their mission encompasses more than just providing funds. They aim to create a supportive ecosystem that includes access to resources, a strong network, and mentorship to help transform ideas into successful businesses. ASIF wants to be the platform that helps future entrepreneurs launch their companies. They've supported 25 startups since inception.
Askeladden & Co
Askeladden & Co focuses on enabling great entrepreneurs to build great companies, particularly those that simplify the lives of customers and employees through technology. They identify opportunities by researching industries and companies, aiming to create significant value and improve the lives of colleagues, customers, and society. Their approach involves co-founding companies, providing capital to develop a concept and achieve product-market fit, and offering operational support to handle administrative tasks. They look for companies that can achieve profitable growth, aligning with their business principles of providing high-quality, affordable goods to customers, sustainable jobs for colleagues, and benefiting society through innovation and value creation.
Aspire11
Aspire11 deploys pension-backed capital to empower European VC investors and founders with patient, long-term funding for enduring innovation without short-term exit pressures.[1][2]
Aspirity Partners
Aspirity Partners is a next-generation pan-European private equity firm focused on partnering with European Financial and Enterprise Technology services companies. The firm targets asset-light businesses capitalizing on long-term secular trends to deliver value acceleration. They focus on B2B mission-critical solutions with highly recurring and scalable business models. The firm’s investment strategy centers around Pan-European Growth and Growth Buyouts, making equity investments between €50-€150 million. They offer flexible capital across majority and strategic minority ownership positions, emphasizing a partnership-focused approach to achieving full potential. Aspirity Partners focuses on a thematic investment strategy, targeting partnership opportunities with deep insight into the underlying markets, complexity of proposition or ecosystem, and tangible opportunities to support companies to achieve their full potential. They unlock transformative growth through their proprietary “Vital Few” framework – prioritised high-impact initiatives that drive accelerated growth, internationalisation, strategic expansion, and operational excellence. The Aspirity team brings decades of sector-relevant investment experience from leading private equity firms globally, enabling deep specialism in targeted markets. The team is amplified by a network of leading founders and executives - collectively, Innovators & Leaders. This partnership-centric engagement model enables Aspirity to drive high-impact initiatives, accelerate internationalisation, and unlock transformative growth for portfolio companies. The firm emphasizes a performance-led, technology-first culture, and a commitment to responsible investment and long-term value creation. They prioritize thematically aligned markets leveraging deep sector experience and work closely with management teams to deliver the “Vital Few” initiatives. Their core values revolve around high conviction, high integrity, and high energy.
Assist Ventu
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Astelia
Venture-Capital-Firma, die in wachstumsstarke Technologieunternehmen investiert.
Astellas Venture Management LLC
Astellas Venture Management (AVM) is the wholly-owned venture capital organization within Astellas Pharma, dedicated to supporting pre-clinical, cutting-edge science that can bring value to patients. With over 20 years of experience, AVM provides equity investments to private, early-stage companies developing therapeutic programs and platform technologies, helping them advance their innovations faster. AVM operates as a strategic investor, focusing on science that enhances the current Astellas R&D pipeline or catalyzes new directions in discovery research. Their investment approach is grounded in a "Pharma View," leveraging their extensive experience in the pharmaceutical industry to provide portfolio companies with invaluable information and expertise to support their growth. Furthermore, AVM can facilitate dialogue between its portfolio companies and Astellas Pharma for potential future collaborations. AVM targets privately owned early-stage biotechnology companies focused on therapeutics programs and platform technologies for drug discovery and development. To be considered for equity investment, the program stage should be in the preclinical phase. Their areas of interest align with the innovative therapeutic approaches that mirror Astellas Pharma's R&D strategy, particularly those addressing unmet medical needs and offering unprecedented treatments that are likely to be realized in the near future. AVM differentiates itself by providing portfolio companies with a "Pharma View" derived from its long-standing experience in the pharmaceutical industry. This provides portfolio companies with invaluable information and pharma expertise to support their growth. They also facilitate dialogue between portfolio companies and Astellas Pharma, fostering opportunities for future collaborations.